The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Taro Pharmaceutical Industries Ltd

NYSE: TARO
Last

(U.S.) $142.46

Today's change+0.16 +0.11%
Updated July 2 4:07 PM EDT. Delayed by at least 15 minutes.
 

Taro Pharmaceutical Industries Ltd

NYSE: TARO
Last

(U.S.) $142.46

Today's change+0.16 +0.11%
Updated July 2 4:07 PM EDT. Delayed by at least 15 minutes.

Taro Pharmaceutical Industries Ltd up (U.S.)$0.16

Taro Pharmaceutical Industries Ltd closed up Thursday by (U.S.)$0.16 or 0.11% to (U.S.)$142.46. Over the last five days, shares have lost 1.28% and are down 3.87% for the last year to date. This security has underperformed the S&P 500 by 4.06% during the last year.

Key company metrics

  • Open(U.S.) $142.50
  • Previous close(U.S.) $142.30
  • High(U.S.) $142.98
  • Low(U.S.) $139.00
  • Bid / Ask-- / --
  • YTD % change-3.87%
  • Volume93,043
  • Average volume (10-day)66,256
  • Average volume (1-month)62,322
  • Average volume (3-month)63,441
  • 52-week range(U.S.) $130.45 to (U.S.) $173.00
  • Beta0.58
  • Trailing P/E12.58×
  • P/E 1 year forward11.29×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $11.32
Updated July 2 4:07 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+56.27%

Based on its net profit margin of 56.27%, Taro Pharmaceutical Industries Ltd is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.30%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q3/2015Q2/2015Q1/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014
Revenue244238251130
Total other revenue--------
Total revenue244238251130
Gross profit20019319885
Total cost of revenue45445345
Total operating expense91789176
Selling / general / administrative22212222
Research & development24131415
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)002-7
Other operating expenses, total--------
Operating income15415916054
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax19017117051
Income after tax15314314446
Income tax, total3728265
Net income15214214346
Total adjustments to net income--------
Net income before extra. items15314314446
Minority interest0000
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items15314314446
Inc. avail. to common incl. extra. items15214214346
Diluted net income15214214346
Dilution adjustment--------
Diluted weighted average shares43434343
Diluted EPS excluding extraordinary itemsvalue per share3.563.333.351.08
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share3.563.333.400.94